Nanjing King-Friend Biochemical Pharmaceutical News

Announcement of Jianyou Co., Ltd. on the action plan to “improve quality, increase efficiency, and focus on return”

Oct 31 00:00

Announcement of Jianyou Co., Ltd. on not revising the Jianyou debt-for-share conversion price downward

Oct 30 00:00

Announcement of Jianyou Co., Ltd. on the approval of its subsidiary product doxycycline hydrochloride for injection from the US FDA

Oct 30 00:00

An indicative announcement by Jianyou Co., Ltd. regarding the “Jianyou Convertible Bonds” expected to meet the revised terms of the conversion price

Oct 23 00:00

Announcement of Jianyou Co., Ltd. on obtaining registration approval for injectable pantoprazole sodium from the State Drug Administration

Oct 15 00:00

Announcement of Jianyou Co., Ltd. on the “Jianyou Bonds” conversion results and stock changes

Oct 9 00:00

Announcement of Jianyou Co., Ltd. on the approval of its subsidiary fluorouracil injection from the US FDA

Sep 26 00:00

Announcement of Jianyou Co., Ltd. on its subsidiary obtaining a drug registration certificate for oxaliplatin injections from the State Drug Administration

Sep 10 00:00

Announcement from nanjing king-friend biochemical pharmaceutical regarding the completion of industrial and commercial change registration.

Aug 23 00:00

Announcement by Nanjing King-Friend Biochemical Pharmaceutical on its subsidiary's product, Lidocaine Hydrochloride Injection, receiving approval from the United States Food and Drug Administration (FDA).

Aug 1 00:00

Announcement on Subsidiary of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Obtaining the Registration Certificate for Injection Azacitidine by the National Medical Products Administration.

Jul 20 00:00

Announcement of Jianyou Co., Ltd. on the “Jianyou Bonds” conversion results and stock changes

Jul 2 00:00

Announcement on the Adjustment of Conversion Price of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Convertible Bonds

Jul 2 00:00

Announcement from Nanjing King-Friend Biochemical Pharmaceutical on obtaining the registration certificate for Ruijiaenosine injection from the National Medical Products Administration.

Jun 29 00:00

Announcement by Nanjing King-friend Biochemical Pharmaceutical regarding the purchase of pharmaceutical batch files by its wholly-owned subsidiary.

Jun 28 00:00

Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. publicly issued convertible corporate bonds that can be tracked and rated in 2024.

Jun 27 00:00

Nanjing King-Friend Biochemical Pharmaceutical's announcement regarding the tracking rating results of the company's convertible bonds due in 2024.

Jun 27 00:00

Announcement on the optional redemption of the Nanjing King-Friend convertible bonds.

Jun 26 00:00

Announcement of Nanjing King-Friend Biochemical Pharmaceutical receiving pharmaceutical registration certificate for Palonosetron hydrochloride injection from the National Medical Products Administration.

Jun 26 00:00

Nanjing King-Friend Biochemical Pharmaceutical hereby issues a notice regarding the suspension of consecutive trading of the "King-Friend Convertible Bond" during the implementation of equity distribution.

Jun 25 00:00